Signaturefd LLC Has $1.29 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Signaturefd LLC trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 16.4% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 18,729 shares of the biopharmaceutical company’s stock after selling 3,663 shares during the period. Signaturefd LLC’s holdings in Gilead Sciences were worth $1,285,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in GILD. Norges Bank bought a new position in shares of Gilead Sciences in the 4th quarter valued at approximately $1,301,624,000. The Manufacturers Life Insurance Company increased its position in Gilead Sciences by 78.8% in the 4th quarter. The Manufacturers Life Insurance Company now owns 7,632,000 shares of the biopharmaceutical company’s stock worth $618,268,000 after buying an additional 3,362,505 shares during the period. Vanguard Group Inc. increased its position in Gilead Sciences by 2.6% in the 1st quarter. Vanguard Group Inc. now owns 114,732,575 shares of the biopharmaceutical company’s stock worth $8,404,161,000 after buying an additional 2,910,147 shares during the period. Wellington Management Group LLP increased its position in Gilead Sciences by 14.4% in the 4th quarter. Wellington Management Group LLP now owns 18,630,134 shares of the biopharmaceutical company’s stock worth $1,509,227,000 after buying an additional 2,350,550 shares during the period. Finally, Swedbank AB bought a new position in Gilead Sciences in the 1st quarter worth approximately $134,489,000. 83.67% of the stock is owned by institutional investors.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 5,490 shares of the stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total value of $406,150.20. Following the transaction, the insider now directly owns 114,979 shares in the company, valued at approximately $8,506,146.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the transaction, the insider now directly owns 96,380 shares in the company, valued at approximately $6,614,559.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Johanna Mercier sold 5,490 shares of the firm’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total value of $406,150.20. Following the completion of the transaction, the insider now owns 114,979 shares in the company, valued at $8,506,146.42. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock traded down $0.45 during midday trading on Friday, reaching $79.00. The company had a trading volume of 6,204,884 shares, compared to its average volume of 7,175,005. The stock has a fifty day simple moving average of $72.93 and a 200 day simple moving average of $70.32. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $87.86. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31. The company has a market capitalization of $98.42 billion, a price-to-earnings ratio of 219.44, a price-to-earnings-growth ratio of 3.37 and a beta of 0.18.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 27th. Shareholders of record on Friday, September 13th will be given a $0.77 dividend. The ex-dividend date of this dividend is Friday, September 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.90%. Gilead Sciences’s payout ratio is 855.56%.

Wall Street Analysts Forecast Growth

GILD has been the topic of several recent analyst reports. Royal Bank of Canada lifted their price target on Gilead Sciences from $71.00 to $72.00 and gave the stock a “sector perform” rating in a research report on Friday, August 9th. Truist Financial lifted their price target on Gilead Sciences from $82.00 to $83.00 and gave the stock a “hold” rating in a research report on Thursday, August 15th. BMO Capital Markets raised their target price on Gilead Sciences from $80.00 to $85.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Thursday, August 15th. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $70.00 target price on shares of Gilead Sciences in a report on Friday, August 9th. Twelve equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and an average price target of $81.94.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.